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Abstract
Sensory neuropathies are the most common neurological complication of HIV. Of these, distal sensory polyneuropathy (DSP)
is directly caused by HIV infection and characterized by length-dependent axonal degeneration of dorsal root ganglion (DRG)
neurons. Mechanisms for axonal degeneration in DSP remain unclear, but recent experiments revealed that the HIV glyco-
protein gp120 is internalized and localized within axons of DRG neurons. Based on these findings, we investigated whether
intra-axonal gp120 might impair fast axonal transport (FAT), a cellular process critical for appropriate maintenance of the
axonal compartment. Significantly, we found that gp120 severely impaired both anterograde and retrograde FAT. Providing a
mechanistic basis for these effects, pharmacological experiments revealed an involvement of various phosphotransferases in
this toxic effect, including members of mitogen-activated protein kinase pathways (Tak-1, p38, and c-Jun N-terminal Kinase
(JNK)), inhibitor of kappa-B-kinase 2 (IKK2), and PP1. Biochemical experiments and axonal outgrowth assays in cell lines and
primary cultures extended these findings. Impairments in neurite outgrowth in DRG neurons by gp120 were rescued using a
Tak-1 inhibitor, implicating a Tak-1 mitogen-activated protein kinase pathway in gp120 neurotoxicity. Taken together, these
observations indicate that kinase-based impairments in FAT represent a novel mechanism underlying gp120 neurotoxicity
consistent with the dying-back degeneration seen in DSP. Targeting gp120-based impairments in FAT with specific kinase
inhibitors might provide a novel therapeutic strategy to prevent axonal degeneration in DSP.
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Introduction
Distal sensory polyneuropathy (DSP) is a frequent compli-
cation of human immunodeﬁciency virus (HIV) infection
that has persisted despite tight viral control by combination
antiretroviral therapy (Kranick and Nath, 2012). A major
pathological characteristic of DSP is progressive, dying-
back degeneration of dorsal root ganglion (DRG) axons
(Keswani et al., 2002). DSP patients suﬀer from excruciat-
ing pain (Dorsey and Morton, 2006); yet, there is a dearth
of eﬀective treatments (Phillips et al., 2010). A signiﬁcant
body of research has documented the neurotoxicity of the
HIV glycoprotein gp120 (Brenneman et al., 1988; Toggas
et al., 1994; Lannuzel et al., 1995; Meucci and Miller, 1996;
Hesselgesser et al., 1998; Meucci et al., 1998; Singh et al.,
2005; Kaul et al., 2007; Bachis et al., 2009), which is over-
produced and shed from the viral capsid (Schneider et al.,
1986). Further, evidence has accumulated for direct toxicity
by gp120 on DRG neurons (Hesselgesser et al., 1998;
Bodner et al., 2004; Wilkerson et al., 2012), suggesting
that gp120 might play a causal role in DSP.
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While gp120 has been shown to cause axonal degener-
ation (Melli et al., 2006; Robinson et al., 2007) and apop-
tosis (Hesselgesser et al., 1998; Bachis et al., 2003; Bodner
et al., 2004; Bachis et al., 2006), the underlying mechan-
isms upstream of these events remain to be elucidated.
Interestingly, recent experimental evidence showing
internalization and intra-axonal location of gp120 in
DRG neurons (Berth et al., 2015) suggests the possibility
of neurotoxicity by intra-axonal gp120.
The extreme polarization of DRG neurons with long
axons places remarkable transport demands on these
cells, since virtually all proteins must be transported
from their site of synthesis in the neuronal cell bodies.
This daunting task depends upon fast axonal transport
(FAT), a cellular process critical for proper functioning
and maintenance of axons and synapses (Morﬁni, 2012).
Signiﬁcantly, genetic and experimental evidence linked
impairments in FAT to axonal degeneration in various
diseases featuring dying-back degeneration of neurons
(Morﬁni, You, et al., 2009). The slowly progressive and
subclinical manifestation of DSP (Keswani et al., 2002)
follows an established pattern in dying-back neuropathies
linked by dysregulation of FAT, termed dysferopathies
(Morﬁni, You, et al., 2009). In a DSP model using simian
immunodeﬁciency virus-infected macaques, distal axons
of peripheral nerves showed an accumulation of damaged
mitochondria (Lehmann et al., 2011), suggestive of alter-
ations in FAT. Additionally, gp120 was found to activate
the stress-activated protein kinases, p38 mitogen-acti-
vated protein kinase (MAPK), and c-Jun N-terminal
Kinase (JNK) in rodent models of DSP (Milligan et al.,
2001; Bodner et al., 2004; Wilkerson et al., 2012), and
these kinases are known to regulate FAT by phosphor-
ylating molecular motors (Morﬁni et al., 2006; Morﬁni
et al., 2013). Together, these precedents raised the possi-
bility that gp120 might alter FAT by promoting abnor-
mal activation of protein kinases. However, eﬀects of
gp120 on FAT have not been examined.
The aim of this study was to deﬁne the eﬀect of intra-
axonal gp120 on FAT. Studies using the isolated squid
axoplasm preparation indicated that gp120 profoundly
impaired both anterograde and retrograde FAT through
abnormal activation of regulatory kinases for FAT. With
the ﬁnding that both p38 MAPK and JNK mediated
inhibition of FAT, the upstream activator of p38
MAPK and JNK was narrowed down to the MAP3K
Tak-1. Interestingly, gp120 was also found to activate
inhibitor of kappa B kinase (IKK)-2 downstream of
Tak-1, which represents a novel regulatory pathway for
FAT. Extending these ﬁndings to mammalian sensory
neurons, axonal growth assays conﬁrmed a critical role
of Tak1 in the axonal pathology associated with gp120
treatment. Collectively, these studies demonstrate a novel
toxic mechanism for gp120 that is consistent with the
dying-back pattern of neuronal degeneration in DSP.
Materials and Methods
Antibodies and Reagents
The following primary antibodies were used: anti-KHC
(H2 clone; [DeBoer et al., 2008]), anti-p38 MAPK (Cell
Signaling #9212), anti-phospho-p38 MAPK (Cell
Signaling #9215), anti-dynein intermediate chain 74-1
clone antibody (Santa Cruz #sc-13524), and anti-tubulin
DM1A clone antibody (Sigma–Aldrich #T9026). The fol-
lowing secondary antibodies were used: Jackson 111-035-
062 HRP-conjugated goat anti-mouse IgG, Jackson 111-
035-144 HRP-conjugated goat anti-rabbit IgG, and
Amersham PA45010 Cy5-tagged goat anti-mouse IgG.
AMD3100 (AMD) and gp120 BaL were obtained from
the National Institutes of Health AIDS Research and
Reference Reagent Program. Recombinant gp120 IIIB
was purchased from Immunodiagnostics (#1001).
SB203580 (#559389), okadaic acid (#495620), SP600125
(#420119), I-2 (#14-162), (5Z)-7-oxozeaenol (#499610),
and IKK Inhibitor XII (#401491) were obtained from
Calbiochem. MW01-2-069A-SRM is a small molecule
drug developed at Northwestern University and
described in (Munoz et al., 2007). Recombinant IKK-2
was obtained from Signal Chem. The DVD peptide was
synthesized at the UIC Biologic Resources Laboratory
facility. ING-135 was a gift from Allen Kozikowski
(UIC), and CEP-11004 was a gift from Cephalon.
F11 Cell Culture
F11 cells (a generous gift from Dr. Richard Miller of
Northwestern University) were grown in high glucose
DMEM media (Invitrogen), supplemented with 10%
fetal bovine serum, 10% glutamax, and 10,000 U/ml
penicillin-streptomycin; 100mm-petri dishes were coated
with 0.1mg/ml poly-L-lysine (Sigma) and rinsed four
times with autoclaved, deionized water for half an hour
each; and 150,000 cells were added to each petri dish.
Cells were maintained at 37 C in 5% CO2 and 95%
O2. To diﬀerentiate the F11 cells, 24 hr after plating the
amount of fetal bovine serum was reduced to 5%, and
then 24 hr after that the cells were treated with 0.5mM
dibutryl-cAMP (Sigma) in media with 0.5% fetal bovine
serum for 4 days.
Cell Lysates
After 4 days of 0.5mM dibutryl-cAMP (Sigma) treat-
ment, F11 cells were treated with 5 nM gp120
(Immunodiagnostics) for 5, 15, or 30min. An experimen-
tal group of cells were ﬁrst treated with 2 mM AMD3100
for 1 hr at 37C prior to treatment with 5 nM gp120 for 5,
15, or 30min. Treatment with phosphate-buﬀered saline
(PBS), the gp120 diluent, was used as a negative control.
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After treatment, cells were scraped and collected in
700 lL lysis buﬀer (1% sodium dodecyl sulfate in PBS,
pH7.4) and sonicated for two 3-sec bursts each. Cells
were spun at 14,000 rpm at 4C in a Beckman tabletop
centrifuge. Protein concentration of clariﬁed lysates was
determined using a bicinchoninic acid assay kit (Pierce).
Sample buﬀer was added to the clariﬁed supernatants,
and the samples were placed in the 80 C freezer prior
to analysis via sodium dodecyl sulfate polyacrylamide gel
electrophoresis.
Immunoblots
Protein samples were separated using 4%–12% bis/tris
MOPS gradient gel (Invitrogen) and transferred to
Immobilon-P transfer membranes (polyvinylidene ﬂuor-
ide, Millipore) at 0.4 Amps for 2 hr in 1X Tobin buﬀer.
Membranes were blocked at room temperature for 60min
with 5% (w/v) nonfat dried milk in PBS or tris-buﬀered
saline (TBS) with 0.1% Tween-20 for phospho-p38
MAPK antibody. Sodium orthovanadate (1mM) and
sodium ﬂuoride (10mM) were added to TBS in all incu-
bation steps involving the use of phosphoantibodies.
Primary antibodies in 1% bovine serum albumin (BSA)
or 5% BSA (phospho-p38 MAPK) were added overnight
at 4 C with gentle rocking. Primary antibodies were
washed 3 10min with PBST (0.25% Tween-20) or
TBST (0.1% Tween-20), and secondary antibodies were
added for 1 hr at 4C with gentle rocking. Membranes
were again washed 3 10min and visualized with ECL
(Amersham) and exposed on ﬁlm (Kodak) for HRP sec-
ondary. Immunoreactive band intensities within linear
range were quantitated and analyzed using Quantity
One software (Bio-Rad Laboratories). The student’s t
test was used for statistical analysis. Quantitative data
were expressed as mean  SEM, and signiﬁcance was
determined at p< .05.
Vesicle Motility Assays in Isolated Squid Axoplasm
Axoplasms were extruded from giant axons of the squid
Loligo pealii (Marine Biological Laboratory) as described
(Song et al., 2016). Gp120 IIIB or gp120 BaL was diluted
into X/2 buﬀer (175mM potassium aspartate, 65mM
taurine, 35mM betaine, 25mM glycine, 10mM HEPES,
6.5mM MgCl2, 5mM EGTA, 1.5mM CaCl2, 0.5mM
glucose, pH7.2) supplemented with 5mM ATP and
20 ml added to perfusion chambers. Preparations were
analyzed on a Zeiss Axiomat with a 100, 1.3 n.a. object-
ive, and diﬀerential interference contrast optics.
Hamamatsu Argus 20 and Model 2400 CCD camera
were used for image processing and analysis. Organelle
velocities were measured with a Photonics Microscopy
C2117 video manipulator (Hamamatsu). All experiments
were repeated at least three times. For statistical analysis
in Figures 2(e), 3(d), 4(e), and 5(f), data from 30- to 50-
min time points were pooled. To compare gp120 treat-
ment to heat-inactivated gp120, Student’s two-tailed t test
was used. Analysis of variance (ANOVA) was utilized to
compare the eﬀects of diﬀerent inhibitors to both buﬀer
control and to 10 nM gp120 treatment. Quantitative data
were expressed as mean  SEM, and signiﬁcance was
determined at p< .05.
Primary Rat DRG Neuron Cultures
DRGs were dissected from Sprague-Dawley rat embryos
at gestation Day 15 (Charles River). Pooled DRGs were
dissociated in 2.5% trypsin in 1Hank’s balanced salt
solution (HBSS) for 10min in a 37 C water bath, and
then the tissue was triturated 10 times with a Pasteur
pipet coated with 0.1% BSA in 1HBSS. The DRGs
in trypsin solution were incubated for an additional
10min in the 37 C water bath followed by another
round of trituration and repeated for a total of three
rounds. Fetal bovine serum (10%) was added to the cell
suspension prior to centrifugation and resuspended in
unsupplemented neural basal (NB) medium
(Invitrogen). The DRG neurons were counted and
plated at 300 cells per channel, of the l-Slide VI that
contains a six-channel format (ibidi), previously coated
with 0.5mg/mL poly-L-lysine (Sigma #P1399) and 10 lg/
mL mouse laminin (Invitrogen). The DRG neurons were
initially plated in a NB media mix supplemented with
glutamax, pen-strep, BSA, and B27 (Invitrogen). After
2 to 4 hr, 50% of the initial plating media was changed
with the NB media mix plus nerve growth factor
(Invitrogen), and the neuronal cultures were maintained
under humidiﬁed atmosphere containing 5% CO2 at
37 C. After 24 hr in vitro, during a 50% media change,
the DRG neurons were treated with 2 nM recombinant
gp120 (ImmunoDiagnostics, Inc #1001), 2 nM heat-inac-
tivated recombinant gp120 (gp120 incubated for 1 hr in
37 C water bath), or 2 nM recombinant gp120þ 15 nM
(5Z)-7-oxozeaenol (EMD Millipore #499610) an inhibi-
tor of Tak1, or remained untreated as the control.
Primary DRG Neurite Outgrowth Assays
At 72 hr in vitro and 48 hr posttreatment, the DRG neu-
rons were ﬁxed with a solution containing 10% parafor-
maldehyde, 1PBS, and 8% glutaraldehyde for 20min
at room temperature and then washed with 1HBSS
three times for 5min each. The DRG neurons were
labeled via ﬂuorescent immunocytochemistry of a-tubu-
lin for neurite outgrowth measurements. The ﬁxed DRG
neurons were quenched for 5min with 50 nM NH4Cl in
1PBS to reduce background, washed in 1PBS, per-
meabilized with 0.1% triton for 10min, washed in
1PBS, blocked with 5% milk in 1PBS for 1 hr,
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incubated with DM1a a-tubulin primary antibody (Sigma
#T9026) at 1:1000 in 0.1% triton-PBS overnight at 4 C,
washed in 1PBS, incubated with AF488-conjugated
secondary antibody (Invitrogen #A11029) at 1:400 in
0.1% triton-PBS for 1 hr at room temperature, and
washed in 1PBS, and Vectashield anti-fade mounting
media (Vector Laboratories) was applied to each cham-
ber channel. Each well in the ibidi chambers was imaged
in a series of micrographs that were tiled to allow visual-
ization of the full extent of all neurites in a well for meas-
urement by ﬂuorescent confocal microscopy (Zeiss LSM
710; Zeiss 10/0,30 Plan-NEOFLUAR). The images
were collected and coded by one investigator and subse-
quently analyzed by another investigator blinded to the
experimental condition. The results include the average
percentage of DRG neurons, deﬁned by a neuronal cell
body with neurite extensions, the average percentage of
DRG degenerating neurons, deﬁned by a neuronal cell
body with no neurite extensions, and average neurite out-
growth lengths per DRG neuron, using Zeiss Zen Lite
imaging analysis software with the measurement
module spline tracing feature. Three independent experi-
ments were conducted for each condition, and the quan-
titative results were averaged for each group and
presented as the meanSEM. Statistical signiﬁcance
was determined at p< .05 using one-way ANOVA with
Bonferroni post hoc analysis.
Results
CXCR4 Involvement in the Activation
of p38 MAPK by gp120
Previous studies of DSP indicated that gp120 binding to its
coreceptor CXCR4 activates signaling cascades, including
ones leading to activation of JNK and p38 MAPK
(Bodner et al., 2004; Wilkerson et al., 2012). The interpret-
ation has been that gp120 binding activates the G-protein
coupled receptor CXCR4, causing activation of signaling
cascades (Oh et al., 2001). To further explore the mechan-
ism of p38 MAPK activation, we evaluated kinase activity
in F11 cells diﬀerentiated with dibutryl-cAMP, which are
rat DRG neurons hybridized with mouse neuroblastoma
cells (Ghil et al., 2000). F11 cells were selected for these
experiments since their ability to proliferate and diﬀeren-
tiate avoids heterogeneity of neuronal cell types character-
istic of DRG primary cultures, while retaining similar
characteristics to DRG neurons (Francel et al., 1987;
Shastry et al., 2001). A time course was performed in
which diﬀerentiated F11 cells were treated with 5nM
gp120 for various times. It was found that gp120 transi-
ently activated p38 MAPK 5min after gp120 treatment,
with subsequent deactivation at the later time points of 15
and 30min (Figure 1(a)). To examine the role of CXCR4
activation on this eﬀect, diﬀerentiated F11 cells were
pretreated for 1 hr with 2mMAMD3100, a small molecule
bicyclam that inhibits binding of gp120 to CXCR4 (De
Clercq et al., 1994; Donzella et al., 1998), then with
5 nM gp120. As expected, AMD3100 pretreatment abol-
ished the early activation of p38 MAPK observed 5min
after gp120, demonstrating that transient activation of p38
MAPK depends upon binding of gp120 to CXCR4
(Figure 1). However, activation of p38 MAPK after
30min of gp120 treatment was increased in AMD3100-
pretreated cells (Figure 1), indicating gp120 treatment
might also increase p38 activity though a CXCR4-inde-
pendent pathway. This observation was consistent with
Figure 1. Activation of p38 MAPK by gp120 treatment.
Differentiated F11 cells were treated with 5 nM gp120 for 5, 15, and
30min. The same volume of PBS, the diluent, was added as a
control, and 0.5M sorbitol treatment (5min) was used as a positive
control for p38 MAPK activation. To examine the contribution of
CXCR4 activation on p38 MAPK activation, differentiated F11 cells
were incubated with 2mM AMD3100 for 1 hr prior to gp120
treatment. (a) A representative Western blot shows p38 MAPK
activation, as shown by an antibody recognizing phosphorylated
(active) p38 MAPK (p-p38). The H2 antibody for kinesin heavy
chain (KHC) was used as a loading control. (b) Quantitation of p38
MAPK activation. Dark gray bars represent no AMD3100 pre-
treatment, and light gray bars represent AMD3100 pretreatment.
The amount of phosphorylated p38 MAPK was significantly
increased after 5min of gp120 treatment compared with control
(p< .05). This transient activation was abolished by pretreatment
with AMD3100 (p< .0001) and was therefore dependent upon
CXCR4 activation. However, AMD3100 treatment unmasked a
CXCR4-independent activation of p38 MAPK after 30min of
treatment (p< .05). Data represent the mean  SEM of the ratio of
phospho-p38 MAPK to total p38 MAPK from 16 separate experi-
ments. *p< .05. #p< .0001.
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our prior studies showing multiple pathways of gp120
internalization (Berth et al., 2015). Analysis with student’s
two-tailed t test (Figure 1(b)) conﬁrmed the activation of
p38 MAPK at 5min after gp120 treatment compared with
treatment with the diluent PBS (p< .05), the abrogation of
p38 MAPK activation by gp120 treatment after
AMD3100 pretreatment (p< .0001), and the activation
of p38 MAPK after 30min of AMD3100 and gp120 treat-
ment compared with 5min of AMD3100 and gp120 treat-
ment (p< .05).
Gp120 Impairs FAT in Isolated Squid Axoplasm
It has previously been demonstrated that a fraction of
gp120 can be internalized independent of binding to
CXCR4 (Berth et al., 2015). Accordingly, AMD3100
treatment of F11 cells prevented activation of p38
MAPK by gp120 treatment after 5min, but not 30min,
suggesting that intracellular gp120 that had been interna-
lized in a pathway independent of CXCR4 (Berth et al.,
2015) might be responsible for kinase activation. Because
DSP exhibits the same pattern of dying-back neuropathy
observed in several unrelated dysferopathies (Morﬁni
et al 2007), we tested whether intracellular gp120 might
also cause dysregulation of FAT.
The isolated squid axoplasm model has proven instru-
mental in deﬁning signaling pathways that regulate both
anterograde (kinesin-1 dependent) and retrograde (cyto-
plasmic-dynein-dependent) FAT, a cellular process crit-
ical for maintenance of the axonal compartment (Brady,
1985; Brady et al., 1985; Brady et al., 1993; Song and
Brady, 2013). Extruded axoplasms were placed on a
coverslip with glass spacers, creating a perfusion chamber
that allows for perfusion of various proteins and inhibi-
tors. Then, video-enhanced contrast diﬀerential interfer-
ence microscopy was performed, and FAT rate values
obtained using a calibrated cursor (Song et al., 2016).
Perfusion of 10 nM gp120 profoundly impaired both
anterograde and retrograde FAT in isolated axoplasms
(Figure 2(b)). In contrast, heat-inactivated gp120 had no
eﬀect on FAT and was comparable to FAT in axoplasms
perfused with buﬀer alone (not shown), suggesting that
the toxic eﬀect of gp120 depends on its conformation and
biological activity (Figure 2(a)). Statistical comparison
between 10 nM gp120 and 10 nM heat-inactivated gp120
revealed a signiﬁcant diﬀerence between both antero-
grade and retrograde FAT rates (Figure 2(e)).
Moreover, FAT was inhibited in both directions when
gp120 was perfused at 100 pM, a more physiologically
relevant concentration (Figure 2(c) and (e)). Some studies
suggested that neurotoxicity diﬀers between gp120 strains
that preferentially bind the coreceptors CXCR4 and
CCR5 (Bachis et al., 2009; Bachis et al., 2010). Based
on these precedents, we compared inhibition of FAT
between gp120 IIIB, which binds to CXCR4, and gp120
BaL, a CCR5-preferring strain. Demonstrating that
inhibition of FAT is conserved across gp120 strains,
both 10 nM gp120 BaL and 10 nM gp120 IIIB produced
similar impairments of FAT (Figure 2(d) and (e)) com-
pared with heat-inactivated gp120. Statistical analysis
with the student’s two-tailed t test demonstrated that
perfusing axoplasms with 10 nM gp120 IIIB, 10 nM
gp120 BaL, or 100 pM gp120 IIIB all signiﬁcantly
decreased anterograde and retrograde FAT compared
with heat-inactivated gp120 (Figure 2(e)).
Gp120 Activates p38 MAPK and JNK to Impair FAT
Previous work established that FAT is regulated by phos-
photransferases (Morﬁni et al., 2002; Morﬁni et al., 2006;
Morﬁni, Burns, et al., 2009). To identify kinases mediating
the inhibitory eﬀect of gp120 on FAT, 10nM gp120 IIIB
was coperfused with various inhibitors of kinases and phos-
phatases known to modulate FAT. Eﬀectiveness of each
inhibitor was evaluated using quantitative analysis with
ANOVA and post hoc Tukey-Kramer tests, by comparing
to both buﬀer control and to 10nM gp120. (Morﬁni et al.,
2006; Morﬁni, You, et al., 2009; Pigino et al., 2009; Morﬁni
et al., 2013). Inhibitors of the protein kinases CK1 and CK2
did not prevent the toxic eﬀect of gp120 on FAT (data not
shown). However, the p38 MAPK and JNK inhibitor
SB203580 (5mM) partially prevented the impairment of
FAT (Figure 3(a)). Quantitative analysis indicated that
this eﬀect was statistically signiﬁcant when compared with
10nM gp120 alone (Figure 3(d)). Although retrograde FAT
rates were restored to buﬀer control levels, anterograde
FAT velocities were still signiﬁcantly lower than those
observed with buﬀer controls (Figure 3(d)). The JNK-spe-
ciﬁc inhibitor SP600125 was coperfused with 10nM gp120
to test the involvement of JNK kinases (Figure 3(c)), or
10mM of the speciﬁc p38 MAPK inhibitor MW01-2-
069A-SRM (MW069A; [Munoz et al., 2007] to evaluate
the involvement of p38 kinases [Figure 3(c)]). Quantitative
analysis revealed that coperfusion of each of these inhibitors
with gp120 partially protected anterograde FAT, as evi-
denced by velocities signiﬁcantly slower than buﬀer control
and signiﬁcantly higher than perfusion with 10nM gp120
alone (Figure 3(d)). However, analysis of retrograde FAT
demonstrated that while MW069A completely protected
FAT, SP600125 showed partial protection. These observa-
tions suggested a more prominent role of p38s than JNKs
on the inhibitory eﬀects elicited by gp120 perfusion.
Collectively, these data suggested that gp120 activates sig-
naling pathways involving both p38 MAPK and JNK to
impair FAT.
Gp120 Activates PP1 to Impair FAT
The observation that p38 MAPK and JNK inhibitors
partially blocked toxic eﬀects of gp120 on FAT suggested
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Figure 2. Inhibition of anterograde and retrograde FAT by gp120. Vesicle motility assays in squid axoplasm. Individual velocity (mm/sec)
rate measurements (arrowheads) are plotted as a function of time (minutes). Black arrowheads and lines represent anterograde, con-
ventional kinesin-dependent FAT rates. Gray arrowheads and lines represent retrograde, CDyn-dependent FAT rates. Perfusion of 10 nM
heat-inactivated gp120 IIIB had no effect on FAT (a), but 10 nM gp120 IIIB profoundly impaired FAT in both anterograde and retrograde
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that gp120 might activate multiple regulatory pathways
for FAT, prompting us to test additional inhibitors.
Interestingly, the decrement of FAT caused by gp120
IIIB was also reduced by the addition of 200 nM okadaic
acid, an inhibitor of serine or threonine phosphatases
PP1, PP2A, and PP2B (IC50: 10 nM; Figure 4(a)).
Quantitative analysis revealed partial protection of FAT
in the anterograde direction and complete protection in
the retrograde direction (Figure 4(e)). To test whether the
activation of serine threonine phosphatases occurred in
Figure 2. Continued
directions (b). The effect of 100 pM gp120 IIIB FATwas comparable to that of 10 nM (c), demonstrating that a physiologically relevant
concentration inhibits FAT. Additionally, perfusion of a CCR5-preferring strain, BaL, showed the same impairment of FAT (d), indicating that
the effect of FAT inhibition by gp120 is conserved across strains. Box plots were generated using pooled values from 30- to 50min time
points for statistical comparisons of each treatment (e). A student’s two-tailed t test performed using pooled values from 30- to 50min
time points demonstrated that 10 nM gp120 IIIB, 100 pM gp120 IIIB, and 10 nM gp120 BaL all significantly inhibit both anterograde and
retrograde FAT, compared with heat-inactivated gp120. *p< .001.
Figure 3. Gp120 activates p38 MAPK and JNK to impair FAT. To identify kinases mediating the toxic effect of gp120 IIIB on FAT,
coperfusion experiments were done. The p38 MAPK and JNK2/3 inhibitor SB203580 partially protected FATwhen coperfused with 10 nM
gp120 (a). Similarly, both the specific JNK inhibitor SP600125 (b) and the specific p38 MAPK inhibitor MW069A (069A) (c) partially
protected FAT, suggesting that both p38 MAPK and JNK may be activated by gp120. Box plots were generated to compare each treatment
(d). ANOVA and post hoc Tukey-Kramer test were used on pooled values from 30- to 50min time points to determine statistical
significance. #p> .05 compared with buffer control, denoting complete protection. *p< .05 compared with both buffer control and to
10 nM gp120, denoting partial protection.
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Figure 4. Gp120-induced inhibition of FAT involves activation of PP1 phosphatase. Since p38 MAPK and JNK inhibition both provided
only partial protection, additional phosphotransferase pathways that affect FATwere examined through coperfusion of axoplasms with
gp120 and appropriate inhibitors. Okadaic acid (OA), a serine-threonine phosphatase inhibitor, partially protected FAT from gp120-induced
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parallel to the activation of p38 MAPK and JNK,
10 nM gp120 IIIB was coperfused with both SB203580
and okadaic acid (Figure 4(b)). Signiﬁcantly, this
treatment completely rescued the impairment of both
anterograde and retrograde FAT caused by gp120 IIIB
(Figure 4(e)).
To narrow down which okadaic acid-sensitive phos-
phatase was activated by gp120 to inhibit FAT, 50nM
of inhibitor I-2 (a PP1-speciﬁc inhibitor) was coperfused
with 10nM gp120 IIIB (Figure 4(c)). Coperfusion of squid
axoplasm with gp120 and I-2 partially protected FAT in
both the anterograde and retrograde directions (Figure
4(e)). Since it has previously been shown that PP1 can
impair FAT by activating GSK3b (Morﬁni et al., 2004),
we coperfused axoplasm with gp120 and 100nM of the
speciﬁc GSK3b inhibitor ING-135. However, ING-135
did not prevent the inhibition of FAT elicited by gp120
(Figure 4(d) and (e)). Together, results from these experi-
ments indicate that gp120 independently activates at least
two signaling pathways in axons with the downstream tar-
gets p38 MAPK, JNK, and another one involving PP1,
both contributing to its toxic eﬀect on FAT.
Gp120 Activates a Tak1 Pathway to Impair FAT
JNK3 and p38 kinases are activated by upstream MAPK
kinases (MAP2Ks), which in turn are activated by
upstream MAP kinase kinases (MAP3Ks; Gallo and
Johnson, 2002), prompting us to determine whether spe-
ciﬁc MAP3Ks mediate the inhibitory eﬀect of gp120 on
FAT. First, an involvement of mixed lineage kinases
(MLKs) was tested in coperfusion experiments using
the pharmacological inhibitor CEP-11004 (Gallo and
Johnson, 2002; Kim et al., 2004). Coperfusing 10 nM
gp120 with 200 nM CEP-11004 did not prevent the inhib-
ition of anterograde FAT by gp120 (Figure 5(a) and (f))
and only showed marginal protection of retrograde FAT,
suggesting the pathway activated by gp120 to impair
FAT does not include activation of MLKs.
MAP3Ks other than MLKs, which can also activate
both p38 and JNK include Tak1 and Ask1 (Gallo and
Johnson, 2002). To determine whether other MAP3Ks
mediated gp120-induced impairment of FAT, additional
inhibitors were evaluated in coperfusion experiments.
First, gp120 was coperfused with the DVD peptide, a
peptide that competes with docking of MAP2Ks to a
subset of MAP3Ks (Takekawa et al., 2005).
Interestingly, DVD peptide partially protected the inhib-
ition of anterograde FAT and completely protected
gp120-induced inhibition of retrograde FAT (Figure
5(b)). Extending these ﬁndings, the selective Tak1 inhibi-
tor (5 Z)-7-Oxozeaenol (50 nM) completely prevented the
eﬀects of gp120 in coperfusion experiments (Figure 5(c)),
identifying Tak1 as an upstream MAP3K responsible for
gp120-induced impairment of FAT. Although ANOVA
analysis only showed partial protection of anterograde
FAT, further analysis using the Spearman’s correlation
indicated that FAT did not decline over time.
Since the Tak1 inhibitor (5 Z)-7-Oxozeaenol com-
pletely protected FAT, activation of PP1 is also likely
to occur in a pathway downstream of Tak1.
Interestingly, Tak1 was shown to interact with PP1
(Platholi et al., 2014), and PP1 mediates activation of
the inhibitor of IKK complex by Tak1, which leads to
IKK-2-induced activation of nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-kB; Mitsuhashi
et al., 2008). To determine whether this pathway contrib-
uted to inhibition of FAT by gp120, recombinant IKK-2
(Signal Chem) was perfused into axoplasm. IKK-2 inhib-
ited both anterograde and retrograde FAT (Figure 5(d)),
revealing a novel eﬀect of IKK-2 on FAT. In addition,
coperfusion of gp120 with the IKK-2 inhibitor XII
resulted in a partial protection of anterograde FAT and
a complete protection of retrograde FAT (Figure 5(e) and
(f)), demonstrating that IKK-2 is a downstream target of
Tak1 to impair FAT. Taken together, experiments using
the squid axoplasm preparation indicate that intra-
axonal gp120 causes dysregulation of FAT by promoting
abnormal activation of Tak 1, which in turn promotes
activation of multiple signaling cascades comprising spe-
ciﬁc kinases and phosphatases.
Gp120 Activation of a Tak1 Pathway Also Impairs
Sensory Neuron Neurite Outgrowth
Results from squid axoplasm experiments indicated that
gp120-induced impairment of FAT is mediated by Tak1
activation. To evaluate the relevance of these ﬁndings to
Figure 4. Continued
FAT impairment (a). Coperfusion with both OA and SB203580 (which inhibits JNK3 and p38s) had an additive effect to completely protect
FAT (b), suggesting that phosphatase activation by gp120 occurs in parallel to JNK and p38 MAPK activation. To narrow down the
phosphatase activated by gp120, the specific inhibitor of PP1 I–2 was tested and found to partially protect FAT (c), indicating that PP1
partially mediates the effect of gp120 on FAT. Since PP1 is known to activate GSK-3b to inhibit FAT (Morfini et al., 2004; Kanaan et al.,
2011), this pathway was tested using a GSK-3b inhibitor ING-135. However, ING-135 did not protect anterograde FATwith marginal
protection in the retrograde direction (d). ANOVA and post hoc Tukey-Kramer test were used on pooled values from 30- to 50min time
points to determine statistical significance. #p> .05 compared with buffer control, denoting complete protection from gp120 impairment of
FAT. *p< .005 compared with both buffer control and to 10 nM gp120, denoting partial protection from gp120 impairment of FAT. p> .05
compared with 10 nM gp120, denoting lack of protection from gp120 impairment of FAT.
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Figure 5. Gp120 activates the MAP3K Tak1 to impair FAT. To determine upstream activators of JNK and p38 MAPK mediating the effects
of gp120 on FAT, coperfusion experiments were done using various MAP3K inhibitors. The MLK inhibitor CEP-11004 did not protect FAT
from gp120 impairment (a), indicating that gp120 does not activate p38s and JNKs through an MLK-dependent pathway. However, the DVD
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DSP, the potential for gp120 to aﬀect neurites projecting
from primary sensory neurons via Tak1 was assessed.
Neurite outgrowth measurements were made on DRG
cultured neurons prepared from E15 rat embryos.
Representative photomicrographs are presented in
Figure 6 of primary DRG neurons that were left
untreated (Figure 6(a)) or treated with 2 nM gp120
(Figure 6(b)), 2nM gp120þ 15 nM (5Z)-7-oxozeaenol
(Tak1 inhibitor; Figure 6(c)), or 2 nM heat-inactivated
gp120 (Figure 6(d)). The treatment was initiated 24 hr
Figure 5. Continued
peptide, which blocks conserved docking domains of a subset of MAP3Ks, did partially protect the toxic effect of gp120 on FAT (b),
demonstrating that one or more DVD peptide-sensitive MAP3Ks mediate p38 MAPK and JNK activation by gp120. Extending these
findings, the specific Tak1 MAP3K inhibitor (5 Z)-7-Oxozeaenol protected FAT in coperfusion experiments with gp120 (c). Since the Tak1
inhibitor showed strong protection, it was postulated that the activation of PP1 is downstream of Tak1 activation and a kinase downstream
of Tak1 that is regulated by PP1, IKK-2, was tested. Perfusion of IKK-2 into isolated axoplasm inhibited both anterograde and retrograde
FAT (d). Further, coperfusion of axoplasms with gp120 and the selective inhibitor of IKK-2 (Inhibitor XII) partially protected FAT
impairments (e), indicating a role for IKK activation in FAT inhibition by gp120. ANOVA and post hoc Tukey-Kramer test were used on
pooled values from 30- to 50min time points to determine statistical significance. #p> .05 compared with buffer control, denoting
complete protection. *p< .005 compared with both buffer control and to 10 nM gp120, denoting partial protection. p> .05 compared with
10 nM gp120, denoting lack of protection.
Figure 6. Gp120 impairs neurite outgrowth through a Tak1-dependent mechanism. Primary rat dorsal root ganglion (DRG) neurons
were treated with gp120 to determine whether gp120 altered neuronal morphology via the ability to grow or maintain neurite extensions.
Representative photomicrographs illustrate DRG neurons that were untreated (a), treated with 2 nM gp120 (b), 2 nM gp120 plus 15 nM
(5 Z)-7-oxozeaenol (c), or 2 nM heat-inactivated gp120 (d). Scale bars indicate 100 mm. The average percentage of DRG neurons exhibiting
neurite extensions (e); calculated from separating the DRG neurons into two categories, one included counts of DRG neurons that
displayed neurites and the other included counts of DRG neurons that lacked neurites. The average neurite outgrowth length per DRG
neuron was determined by measuring all neurites within the sample and dividing by the number of DRG neurons that displayed neurites (f),
results given in micrometers. All results averaged from three independent experiments that examined 3,154 neurons in total, including
2,374 neurons exhibiting neurites and 780 neuronal cell bodies without neurites. *p< .05 compared with untreated control, gp120þ (5 Z)-
7-oxozeaenol, and heat-inactivated gp120 groups.
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after plating (1 day in vitro), and all groups were ﬁxed at
48 hr posttreatment (3 days in vitro) and immunostained
with DM1A, primary antibody speciﬁc to a-tubulin for
analysis of neurite outgrowth.
DRG neurons were separated into two categories
according to their morphology, those that had neurites
extending from the perikarya and those that did not have
neurite extensions. Extracellular treatment with gp120
resulted in a signiﬁcant reduction in the percentage of
DRG neurons that exhibited neurite extensions
(55 7%; p< .05), compared with untreated DRG neu-
rons (82 0.8%; Figure 6(a), (b), and (e)). Examination
of neurite outgrowth measurements revealed that treat-
ment with gp120 also resulted in a signiﬁcant reduction in
the average neurite outgrowth length per DRG neuron
(845 199 mm/DRG neuron; p< .05), compared with
untreated DRG neurons (1452 73 mm/DRG neuron;
Figure 6(a), (b), and (f)). However, cotreatment with
gp120þ (5 Z)-7-oxozeaenol demonstrated a protective
eﬀect by signiﬁcantly increasing both the percentage of
DRG neurons exhibiting neurite extensions (78 7%;
Figure 6(a), (c), and (e)) and the average neurite out-
growth length per DRG neuron (1281 67 mm/DRG
neuron; Figure 6(a), (c), and (f)), compared with DRG
Figure 7. Diagram depicting kinase pathways activated by gp120. The use of pharmacological inhibitors in axonal transport studies here
delineated novel signaling pathways by which gp120 impairs FAT. Gp120 was found to activate, directly or indirectly (dotted line) the
MAP3K Tak1. Tak1 in turn activates at least two independent signaling pathways. In one pathway, Tak1 activates the IKK complex through a
mechanism that requires PP1 activity and leads to activation of IKK-2. How IKK-2 inhibits FAT is currently unknown and depicted by the
dotted line. In the second pathway, Tak1 activates canonical MAP2Ks which in turn, promote activation of both p38 MAPK and JNK. Both
p38 MAPK and JNK are known to phosphorylate kinesin to inhibit FAT. (5 Z)-7-Oxozeaenol: Tak-1 inhibitor. DVD peptide blocks
conserved docking domains to inhibit certain MAP3K’s. Okadaic acid inhibits serine or threonine phosphatases. I-2: specific inhibitor of the
serine or threonine phosphatase PP1. Inhibitor XII: a specific inhibitor of IKK-2. MW069A: a specific inhibitor of p38 MAPK. SP600125: a
specific inhibitor of JNK. SB203580: an inhibitor of p38 MAPK and JNK3.
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neurons with gp120 alone. DRG neurons treated with
heat-inactivated gp120 did not diﬀer signiﬁcantly from
untreated controls for neurite extensions (80 4%;
Figure 6(a), (d), and (e)) or for the average neurite out-
growth length per DRG neuron (1490 92 mm/DRG
neuron; Figure 6(a), (d), and (f)), compared with
untreated DRG neurons. These results suggest that
gp120 reduces the ability of DRG sensory neurons to
maintain neurite extensions, and gp120’s negative
impact on neurite outgrowth and sensory neuron morph-
ology can be reversed by a Tak1-speciﬁc inhibitor.
Together, these results are consistent with results
obtained with the isolated axoplasm preparation, provid-
ing further evidence for a link between gp120-mediated
Tak1 activation and neurite degeneration.
Discussion
Although DSP is the most prevalent neurological compli-
cation of HIV, aﬀecting close to 30% of patients, its
pathogenesis remains unclear and treatments are limited
(Phillips et al., 2010). Proposed pathological mechanisms
of DSP include indirect neurotoxicity by activation of
macrophages and direct neurotoxicity by release of viral
proteins, such as gp120, which interact with DRG neu-
rons. A recent study indicated that gp120 is internalized
by DRG neurons and localizes within their axons (Berth
et al., 2015), suggesting the possibility of an intra-neuro-
nal mechanism for gp120 to cause neurotoxicity.
Several studies utilizing transgenic models or gp120
treatments have linked gp120 to axonal degeneration
(Herzberg and Sagen, 2001; Michaud et al., 2001;
Keswani et al., 2006; Melli et al., 2006; Robinson et al.,
2007), but the underlying mechanisms underlying for this
critical pathogenic event in DSP remained unclear.
Induction of neuronal apoptosis has been the most com-
monly studied parameter for gp120 neurotoxicity (Zheng
et al., 1999; Bachis et al., 2003; Bodner et al., 2004; Singh
et al., 2004; Singh et al., 2005),. However, apoptosis is not
a major feature of DSP, and targeting cell death has not
been eﬀective at ameliorating disease in dying-back neu-
ropathies (Sagot et al., 1997; Chiesa et al., 2005; Gould
et al., 2006), Instead, the pattern of sensory neuron
degeneration in DSP progresses distally to proximally
in a ‘‘stocking and glove’’ fashion (Keswani et al.,
2002), placing DSP in the category of dying-back neuro-
pathies where degeneration represents an early patho-
genic feature that long precedes cell death.
How might intra-neuronal gp120 cause the axonal
degeneration phenotype seen in DSP? One possible mech-
anism is through impairments in FAT. Loss-of-function
mutations of the motor proteins kinesin or CDyn are
suﬃcient to cause dying-back neuropathies (Reid et al.,
2002; Puls et al., 2003; Munch et al., 2005; Ebbing et al.,
2008; Dupuis et al., 2009). Since the concentration of
kinesin is 0.5mM and tubulin is 25 mM in squid axoplasm
(Morris and Lasek, 1984; Brady et al., 1990), the concen-
tration of perfused gp120 was not high enough to cause
sequestration of kinesin or impair FAT through binding
to microtubules (Brady et al., 1990). Further, gp120 per-
fusion did not alter microtubule structure in the squid
axoplasm (data not shown). Therefore, a more plausible
explanation is that the severe eﬀect on FAT elicited by
gp120 results from activation of signaling cascades that
regulate FAT.
Abnormal activation of signaling pathways for regu-
lation of FAT has been implicated in a multiple dying-
back neuropathies, including Alzheimer’s disease (Pigino
et al., 2009; Kanaan et al., 2012), Parkinson’s disease
(Morﬁni et al., 2007; Chu et al., 2012), amyotrophic lat-
eral sclerosis (Bosco et al., 2010; Morﬁni et al., 2013),
spinal bulbar muscular atrophy (Morﬁni et al., 2006),
and Huntington’s disease (Szebenyi et al., 2003;
Morﬁni, You, et al., 2009), leading to the coinage of
‘‘dysferopathies’’ as a term to describe dying-back neuro-
pathies in which impaired FAT has a prominent role
(Morﬁni et al., 2007). To examine whether DSP itself
might be a dysferopathy, the ability of gp120 to alter
the activity of kinases involved in regulation of FAT
was assessed. Previously, gp120 treatment had been
reported to activate JNK (Bodner et al., 2004; Khan
et al., 2004) or p38 MAPK (Hu et al., 2005; Singh
et al., 2005; Medders et al., 2010) in neurons. The
assumption in these studies was that kinase activation
and neurotoxic eﬀects of gp120 were dependent upon
binding to its coreceptor CXCR4, a GPCR that promotes
a transient activation of kinase signaling cascades.
Sustained activation of either JNK or P38 MAPK can
aﬀect FAT (Morﬁni et al., 2006; Morﬁni, You, et al.,
2009; Bosco et al., 2010; Morﬁni et al., 2013), but transi-
ent activation is unlikely to signiﬁcantly aﬀect transport.
However, elimination of the CXCR4 response with
AMD3100 pretreatment unmasked a slower activation
of p38 MAPK after 30min of gp120 exposure.
How might this phosphorylation of p38 MAPK occur
with no CXCR4 activation? Given that a portion of
gp120 internalization in F11 cells was independent of
CXCR4 binding (Berth et al., 2015), the delayed activa-
tion of p38 MAPK, corresponding to the timing of gp120
internalization, could be due to the activation of signaling
cascades by intracellular gp120. This delayed activation
of P38 MAPK would be masked by activation through
CXCR4.
The neurotoxicity of diﬀerent gp120 strains has been a
matter of dispute. Some past studies found that T-tropic
gp120 was more neurotoxic than M-tropic gp120 (Zheng
et al., 1999; Frost et al., 2009; Bachis et al., 2010), but
other studies found similar neurotoxicity for T-tropic and
M-tropic gp120 strains (Yi et al., 2004; Kaul et al., 2007).
The divergent strains T-tropic gp120 IIIB (CXCR4) and
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the M-tropic gp120 BaL (CXCR5) were comparable in
their ability to inhibit FAT in axoplasm, suggesting that
the eﬀect on FAT is likely to be conserved across strains,
even though some studies reported a neuroprotective
eﬀect of CCR5 (Kaul et al., 2007). An explanation for
similar neurotoxic eﬀects between the two strains is that
squid axoplasm is a plasma membrane-free preparation,
so any eﬀects of gp120 seen in these experiments are inde-
pendent of coreceptor activation.
Since the amount of free gp120 in plasma has been
determined to be in the low picomolar to low nanomolar
range (Gilbert et al., 1991; Oh et al., 1992), 100 pM gp120
was perfused to determine if a lower, more physiological
relevant concentration might aﬀect transport. In fact,
100 pM gp120 impaired FAT to a similar extent as
10 nM gp120. The local concentration of gp120 around
DRG neurons has not been directly measured but is likely
higher than plasma concentrations due to the close prox-
imity of infected cells binding to extracellular matrix
components or local glial swelling (Nath, 2002;
Krathwohl and Kaiser, 2004). An important point is
that DSP takes decades to develop, although subclinical
signs are commonly manifested in HIV patients. Thus,
smaller amounts of gp120 internalized by DRG neurons
could gradually compromise neuronal function over dec-
ades by compromising FAT in DRG neurons.
Partial protection of FAT from the eﬀects of gp120
with coperfusion of axoplasm with gp120 and various
inhibitors of kinases and phosphatases identiﬁed various
components of the signaling pathways likely to mediate
gp120 eﬀects on FAT. Partial protection by inhibitors of
p38 MAPK, JNK, and PP1 (Figures 3 and 4) suggested
that gp120 activates p38 MAPK, JNK, and PP1 to inhibit
FAT. In contrast, an inhibitor of TAK1 oﬀered full pro-
tection of FAT from the action of gp120 (Figure 5(c)),
suggesting a critical role for this MAP3K in the signaling
pathways associated with DSP. The additive eﬀect of
MAPK and PP1 inhibitors indicated that PP1 activation
occurred in an independent, parallel pathway to the one
responsible for activation of p38 MAPK and JNK, both
of which may be linked to TAK1.
Additional evidence that gp120 impairs neuronal func-
tion by activation of Tak1 was provided by analyzing
primary DRG neuron neurite extension after exposure
to gp120 in vitro. Exposing primary cultured rat DRG
neurons to gp120 directly aﬀected the outgrowth of neur-
ites, through either inhibition of neurite sprouting or
initiating degeneration of previously extended neurites.
The deleterious eﬀect of gp120 on DRG neurite out-
growth was reversed by concurrent treatment with the
Tak1 inhibitor, (5 Z)-7-oxozeaenol, suggesting that
DRG neurite susceptibility to gp120 exposure is mediated
through Tak1 signaling.
Tak1 MAP3K is well established as an upstream
MAP3K for p38 MAPK and JNK (Gallo and Johnson,
2002), but inhibiting Tak1 also provided complete pro-
tection of FAT, suggesting that activation of PP1 is
downstream of Tak1. Since Tak1 is known to activate
IKK-2 (Sakurai, 2012), and PP1 has been found to inter-
act with the IKK complex to positively regulate IKK-2
activation (Mitsuhashi et al., 2008), the activation of
IKK-2 by gp120 was tested. In fact, recombinant IKK-
2 inhibited anterograde and retrograde FAT, and coper-
fusion of axoplasm with both gp120 and the IKK-2
inhibitor XII exhibited partial protection, indicating
that gp120 activates IKK-2 to inhibit FAT. It is unclear
if PP1 is activated by gp120, or if PP1 activity is required
for Tak1 activation of IKK-2. These results deﬁne a novel
role for IKK-2 in regulation of FAT, which is outside of
its role in activating NF-kB. Indeed, accumulations of
both IKK-2 and its phosphorylated downstream target
IkBa have been detected in axons, primarily in initial
segments and nodes of Ranvier extending into paranodes
(Schultz et al., 2006; Politi et al., 2008). Phosphorylated
IkBa associates with microtubules (Politi et al., 2008),
placing it in an appropriate location to regulate FAT.
IkBa was also reported in association with dynein light
chain through a yeast two-hybrid screen, coimmunopre-
cipitation in cell lines and colocalization in immunoﬂuor-
escence (Crepieux et al., 1997). However, the mechanism
by which IKK-2 or IkBa regulates FAT remains to be
deﬁned. Future experiments will determine whether IKK-
2 or IkBamight directly phosphorylate kinesin or dynein,
or if they activate an intermediate kinase that phosphor-
ylates either motor protein to regulate FAT.
Collectively, results from experiments here revealed a
novel mechanism of neurotoxicity for gp120. Gp120 is
internalized by neurons, then localized and transported
in their axons (Berth et al., 2015). Intra-axonal gp120
inhibits FAT by aﬀecting regulatory signaling cascades.
As impaired FAT promotes axonal pathology, observa-
tions here are consistent with the dying-back neurodegen-
eration seen in DSP. Indeed, pharmacological inhibition
of the signaling pathway through which gp120 inhibits
FAT in isolated axoplasm was suﬃcient to prevent neur-
itic abnormalities in mammalian DRG neurons. This
direct eﬀect of gp120 does not exclude the possibility of
indirect actions, and it is likely that multiple actions of
gp120 synergize to harm DRG neurons. For example, the
activation of CXCR4 by gp120 that leads to p38 MAPK
activation might synergize with p38 MAPK activation
caused by intra-axonal gp120. Additionally, TNF-a has
been strongly implicated in the inﬂammatory response in
the indirect pathway for DSP (Herzberg and Sagen, 2001;
Keswani et al., 2003; Zheng et al., 2011). Intriguingly,
TNF-a activates the NF-kB pathway through Tak1,
which is the same pathway that we have found activated
by intra-axonal gp120. These multiple mechanisms lead-
ing to activation of Tak1 could very well synergize with
each other. Regardless, we propose that impairment of
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FAT by gp120 is a critical step in the pathway to the
development of DSP, making DSP another member of
the class of neurological diseases that can be considered
dysferopathies. Promoting normal regulation of FAT
may represent a promising avenue for therapeutic inter-
ventions for DSP.
Acknowledgments
The authors thank the eorts of Yelena Leitman, Alex Sturbaum, and
Anoopah Singh for assistance with axoplasm assays as well as
CarlitaShen and Kimberly Helseth for contributions to neurite out-
growth assays.
Author Contributions
S. H. B., G. M., and S. T. B. wrote the manuscript; S. H. B., G. M.,
and S. T. B. designed the experiments; S. H. B. performed bio-
chemistry and axoplasm experiments; Y. S., M. S., and S. T. B.
performed axoplasm experiments; N. M. H. and B. W. did neurite
outgrowth experiments; and H. K. did statistical analysis. All
authors reviewed and edited the manuscript.
Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.
Funding
The authors disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: The pro-
ject described was supported by the National Center for Advancing
Translational Sciences, National Institutes of Health, through Grant
TL1TR000049 and by the NIH grant T32MH067631 to SHB; NIH
grants NS066942A to GM; and grants from the National Institutes
of Neurological Disorders and Stroke [NS023868 and NS041170]
to STB; and a pilot grant from the Chicago DCFAR
[P30AI083151], the UIC Center for Clinical and Translational
Sciences, and the Chicago Biomedical Consortium to STB.
References
Bachis, A., Aden, S. A., Nosheny, R. L., Andrews, P. M., &
Mocchetti, I. (2006). Axonal transport of human immunodefi-
ciency virus type 1 envelope protein glycoprotein 120 is found
in association with neuronal apoptosis. The Journal of
Neuroscience, 26, 6771–6780.
Bachis, A., Biggio, F., Major, E. O., & Mocchetti, I. (2009). M- and
T-tropic HIVs promote apoptosis in rat neurons. Journal of
Neuroimmune Pharmacology, 4, 150–160.
Bachis, A., Cruz, M. I., & Mocchetti, I. (2010). M-tropic HIV
envelope protein gp120 exhibits a different neuropathological
profile than T-tropic gp120 in rat striatum. The European
Journal of Neuroscience, 32, 570–578.
Bachis, A., Major, E. O., & Mocchetti, I. (2003). Brain-derived
neurotrophic factor inhibits human immunodeficiency virus-1/
gp120-mediated cerebellar granule cell death by preventing
gp120 internalization. The Journal of Neuroscience, 23,
5715–5722.
Berth, S., Caicedo, H. H., Sarma, T., Morfini, G., & Brady, S. T.
(2015). Internalization and axonal transport of the HIV glyco-
protein gp120. ASN Neuro, 7, 1–15.
Bodner, A., Toth, P. T., & Miller, R. J. (2004). Activation of c-Jun
N-terminal kinase mediates gp120IIIB- and nucleoside analo-
gue-induced sensory neuron toxicity. Experimental Neurology,
188, 246–253.
Bosco, D. A., Morfini, G., Karabacak, N. M., Song, Y., Gros-
Louis, F., Pasinelli, P., . . . Brown, Jr. R. H. (2010). Wild-type
and mutant SOD1 share an aberrant conformation and a
common pathogenic pathway in ALS. Nature Neuroscience,
13, 1396–1403.
Brady, S. T. (1985). A novel brain ATPase with properties expected
for the fast axonal transport motor. Nature, 317, 73–75.
Brady, S. T., Lasek, R. J., & Allen, R. D. (1985). Video microscopy
of fast axonal transport in extruded axoplasm: A new model for
study of molecular mechanisms. Cell Motility, 5, 81–101.
Brady, S. T., Pfister, K. K., & Bloom, G. S. (1990). A monoclonal
antibody against kinesin inhibits both anterograde and retro-
grade fast axonal transport in squid axoplasm. Proceedings of
the National Academy of Sciences of the United States of
America, 87, 1061–1065.
Brady, S. T., Richards, B. W., & Leopold, P. L. (1993). Assay of
vesicle motility in squid axoplasm. Methods in Cell Biology, 39,
191–202.
Brenneman, D. E., Westbrook, G. L., Fitzgerald, S. P., Ennist, D.
L., Elkins, K. L., Ruff, M. R., . . . Pert, C. B. (1988). Neuronal
cell killing by the envelope protein of HIV and its prevention by
vasoactive intestinal peptide. Nature, 335, 639–642.
Chiesa, R., Piccardo, P., Dossena, S., Nowoslawski, L., Roth, K. A.,
Ghetti, B., . . . Harris, D. A. (2005). Bax deletion prevents neur-
onal loss but not neurological symptoms in a transgenic model
of inherited prion disease. Proceedings of the National Academy
of Sciences of the United States of America, 102, 238–243.
Chu, Y., Morfini, G. A., Langhamer, L. B., He, Y., Brady, S. T.,
Kordower, J. H. (2012). Alterations in axonal transport motor
proteins in sporadic and experimental Parkinson’s disease.
Brain, 135, 2058–2073.
Crepieux, P., Kwon, H., Leclerc, N., Spencer, W., Richard, S., Lin,
R., . . . Hiscott, J. (1997). I kappaB alpha physically interacts
with a cytoskeleton-associated protein through its signal
response domain. Molecular and Cellular Biology, 17,
7375–7385.
DeBoer, S. R., You, Y., Szodorai, A., Kaminska, A., Pigino, G.,
Nwabuisi, E., . . . Morfini, G. (2008). Conventional kinesin holo-
enzymes are composed of heavy and light chain homodimers.
Biochemistry, 47, 4535–4543.
De Clercq, E., Yamamoto, N., Pauwels, R., Balzarini, J., Witvrouw,
M., De Vreese, K., . . . Abrams, M. (1994). Highly potent and
selective inhibition of human immunodeficiency virus by the
bicyclam derivative JM3100. Antimicrobial Agents and
Chemotherapy, 38, 668–674.
Donzella, G. A., Schols, D., Lin, S. W., Este, J. A., Nagashima, K.
A., Maddon, P. J., . . . Moore, J. P. (1998). AMD3100, a small
molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.
Nature Medicine, 4, 72–77.
Dorsey, S. G., & Morton, P. G. (2006). HIV peripheral neuropathy:
Pathophysiology and clinical implications. AACN Clinical
Issues, 17, 30–36.
Berth et al. 15
Dupuis, L., Fergani, A., Braunstein, K. E., Eschbach, J., Holl, N.,
Rene, F., . . . Loeffler, J. P. (2009). Mice with a mutation in the
dynein heavy chain 1 gene display sensory neuropathy but lack
motor neuron disease. Experimental Neurology, 215, 146–152.
Ebbing, B., Mann, K., Starosta, A., Jaud, J., Schols, L., Schule,
R., . . . Woehlke, G. (2008). Effect of spastic paraplegia muta-
tions in KIF5A kinesin on transport activity. Human Molecular
Genetics, 17, 1245–1252.
Francel, P. C., Harris, K., Smith, M., Fishman, M. C., Dawson, G.,
Miller, R. J. (1987). Neurochemical characteristics of a novel
dorsal root ganglion X neuroblastoma hybrid cell line, F-11.
Journal of Neurochemistry, 48, 1624–1631.
Frost, B., Jacks, R. L., & Diamond, M. I. (2009). Propagation of tau
misfolding from the outside to the inside of a cell. Journal of
Neurochemistry, 284, 12845–12852.
Gallo, K. A., & Johnson, G. L. (2002). Mixed-lineage kinase con-
trol of JNK and p38 MAPK pathways. Nature Reviews.
Molecular Cell Biology, 3, 663–672.
Ghil, S. H., Kim, B. J., Lee, Y. D., & Suh-Kim, H. (2000). Neurite
outgrowth induced by cyclic AMP can be modulated by the
alpha subunit of Go. Journal of Neurochemistry, 74, 151–158.
Gilbert, M., Kirihara, J., & Mills, J. (1991). Enzyme-linked
immunoassay for human immunodeficiency virus type 1 enve-
lope glycoprotein 120. Journal of Clinical Microbiology, 29,
142–147.
Gould, T. W., Buss, R. R., Vinsant, S., Prevette, D., Sun, W.,
Knudson, C. M., . . . Oppenheim, R. W. (2006). Complete dis-
sociation of motor neuron death from motor dysfunction by Bax
deletion in a mouse model of ALS. The Journal of
Neuroscience, 26, 8774–8786.
Herzberg, U., & Sagen, J. (2001). Peripheral nerve exposure to HIV
viral envelope protein gp120 induces neuropathic pain and
spinal gliosis. Journal of Neuroimmunology, 116, 29–39.
Hesselgesser, J., Taub, D., Baskar, P., Greenberg, M., Hoxie, J.,
Kolson, D. L., . . . Horuk, R. (1998). Neuronal apoptosis induced
by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by
the chemokine receptor CXCR4. Current Biology, 8, 595–598.
Hu, S., Sheng, W. S., Lokensgard, J. R., & Peterson, P. K. (2005).
Morphine potentiates HIV-1 gp120-induced neuronal apoptosis.
The Journal of Infectious Diseases, 191, 886–889.
Kanaan, N. M., Morfini, G. A., Lapointe, N. E., Pigino, G. F.,
Patterson, K. R., Song, Y., . . . Binder, L. I. (2011). Pathogenic
Forms of Tau Inhibit Kinesin-Dependent Axonal Transport
through a Mechanism Involving Activation of Axonal
Phosphotransferases. The Journal of neuroscience: The official
journal of the Society for Neuroscience, 31, 9858–9868.
Kanaan, N. M., Morfini, G., Pigino, G., LaPointe, N. E., Andreadis,
A., Song, Y., . . . Brady, S. T. (2012). Phosphorylation in the
amino terminus of tau prevents inhibition of anterograde
axonal transport. Neurobiology of Aging, 33, 826.e815–e830.
Kaul, M., Ma, Q., Medders, K. E., Desai, M. K., & Lipton, S. A.
(2007). HIV-1 coreceptors CCR5 and CXCR4 both mediate
neuronal cell death but CCR5 paradoxically can also contribute
to protection. Cell Death and Differentiation, 14, 296–305.
Keswani, S. C., Jack, C., Zhou, C., & Hoke, A. (2006).
Establishment of a rodent model of HIV-associated sensory
neuropathy. The Journal of Neuroscience, 26, 10299–10304.
Keswani, S. C., Pardo, C. A., Cherry, C. L., Hoke, A., & McArthur,
J. C. (2002). HIV-associated sensory neuropathies. Aids, 16,
2105–2117.
Keswani, S. C., Polley, M., Pardo, C. A., Griffin, J. W., McArthur,
J. C., Hoke, A. (2003). Schwann cell chemokine receptors medi-
ate HIV-1 gp120 toxicity to sensory neurons. Annals of
Neurology, 54, 287–296.
Khan, M. Z., Brandimarti, R., Patel, J. P., Huynh, N., Wang, J.,
Huang, Z., . . . Meucci, O. (2004). Apoptotic and antiapoptotic
effects of CXCR4: Is it a matter of intrinsic efficacy?
Implications for HIV neuropathogenesis. AIDS Research and
Human Retroviruses, 20, 1063–1071.
Kim, K. Y., Kim, B. C., Xu, Z., & Kim, S. J. (2004). Mixed lineage
kinase 3 (MLK3)-activated p38 MAP kinase mediates trans-
forming growth factor-beta-induced apoptosis in hepatoma
cells. Journal of Neurochemistry, 279, 29478–29484.
Kranick, S. M., & Nath, A. (2012). Neurologic complications of
HIV-1 infection and its treatment in the era of antiretroviral
therapy. Continuum (Minneapolis, Minn.), 18, 1319–1337.
Krathwohl, M. D., & Kaiser, J. L. (2004). HIV-1 promotes quies-
cence in human neural progenitor cells. The Journal of
Infectious Diseases, 190, 216–226.
Lannuzel, A., Lledo, P. M., Lamghitnia, H. O., Vincent, J. D., &
Tardieu, M. (1995). HIV-1 envelope proteins gp120 and
gp160 potentiate NMDA-induced [Ca2þ]i increase, alter
[Ca2þ]i homeostasis and induce neurotoxicity in human embry-
onic neurons. The European Journal of Neuroscience, 7,
2285–2293.
Lehmann, H. C., Chen, W., Borzan, J., Mankowski, J. L., & Hoke,
A. (2011). Mitochondrial dysfunction in distal axons contributes
to human immunodeficiency virus sensory neuropathy. Annals
of Neurology, 69, 100–110.
Medders, K. E., Sejbuk, N. E., Maung, R., Desai, M. K., & Kaul,
M. (2010). Activation of p38 MAPK is required in monocytic
and neuronal cells for HIV glycoprotein 120-induced neurotox-
icity. Journal of Immunology, 185, 4883–4895.
Melli, G., Keswani, S. C., Fischer, A., Chen, W., & Hoke, A.
(2006). Spatially distinct and functionally independent mechan-
isms of axonal degeneration in a model of HIV-associated sen-
sory neuropathy. Brain, 129, 1330–1338.
Meucci, O., Fatatis, A., Simen, A. A., Bushell, T. J., Gray, P. W.,
Miller, R. J. (1998). Chemokines regulate hippocampal neuronal
signaling and gp120 neurotoxicity. Proceedings of the National
Academy of Sciences of the United States of America, 95,
14500–14505.
Meucci, O., & Miller, R. J. (1996). gp120-induced neurotoxicity in
hippocampal pyramidal neuron cultures: Protective action of
TGF-beta1. The Journal of Neuroscience, 16, 4080–4088.
Michaud, J., Fajardo, R., Charron, G., Sauvageau, A., Berrada, F.,
Ramla, D., . . . Kessous-Elbaz, A. (2001). Neuropathology of
NFHgp160 transgenic mice expressing HIV-1 env protein in
neurons. Journal of Neuropathology and Experimental
Neurology, 60, 574–587.
Milligan, E. D., O’Connor, K. A., Armstrong, C. B., Hansen, M. K.,
Martin, D., Tracey, K. J., . . . Watkins, L. R. (2001). Systemic
administration of CNI-1493, a p38 mitogen-activated protein
kinase inhibitor, blocks intrathecal human immunodeficiency
virus-1 gp120-induced enhanced pain states in rats. The
Journal of Pain, 2, 326–333.
Mitsuhashi, S., Shima, H., Li, Y., Tanuma, N., Okamoto, T.,
Kikuchi, K., . . . Ubukata, M. (2008). Tautomycetin suppresses
the TNFalpha/NF-kappaB pathway via inhibition of IKK acti-
vation. International Journal of Oncology, 33, 1027–1035.
16 ASN Neuro
Morfini, G., Burns, M. R., Stenoien, D., & Brady, S. T. (2012).
Axonal transport. In: S. T. Brady, G. Siegel, R. W. Albers, &
D. Price (Eds.). Basic neurochemistry: Principles of molecular,
cellular and medical neurobiology 8th ed. Boston, MA:
Elsevier, pp. 146–164.
Morfini, G., Pigino, G., Beffert, U., Busciglio, J., & Brady, S. T.
(2002). Fast axonal transport misregulation and Alzheimer’s
disease. Neuromolecular Medicine, 2, 89–99.
Morfini, G., Pigino, G., Opalach, K., Serulle, Y., Moreira, J. E.,
Sugimori, M., . . . Brady, S. T. (2007). 1-methyl-4-phenylpyridi-
nium affects fast axonal transport by activation of caspase and
protein kinase C. Proceedings of the National Academy of
Sciences of the United States of America, 104, 2442–2447.
Morfini, G., Pigino, G., Szebenyi, G., You, Y., Pollema, S., Brady,
S. T. (2006). JNK mediates pathogenic effects of polygluta-
mine-expanded androgen receptor on fast axonal transport.
Nature Neuroscience, 9, 907–916.
Morfini, G., Szebenyi, G., Brown, H., Pant, H. C., Pigino, G.,
DeBoer, S., . . . Brady, S. T. (2004). A novel CDK5-dependent
pathway for regulating GSK3 activity and kinesin-driven motil-
ity in neurons. The EMBO Journal, 23, 2235–2245.
Morfini, G. A., Bosco, D. A., Brown, H., Gatto, R., Kaminska, A.,
Song, Y., . . . Brady, S. T. (2013). Inhibition of fast axonal trans-
port by pathogenic SOD1 involves activation of p38 MAP
kinase. PLoS One, 8, e65235.
Morfini, G. A., Burns, M., Binder, L. I., Kanaan, N. M., LaPointe,
N., Bosco, D. A., . . . Brady, S. T. (2009). Axonal transport
defects in neurodegenerative diseases. The Journal of
Neuroscience, 29, 12776–12786.
Morfini, G. A., You, Y. M., Pollema, S. L., Kaminska, A., Liu, K.,
Yoshioka, K., . . . Brady, S. T. (2009). Pathogenic huntingtin
inhibits fast axonal transport by activating JNK3 and phosphor-
ylating kinesin. Nature Neuroscience, 12, 864–871.
Morris, J. R., & Lasek, R. J. (1984). Monomer-polymer equilibria
in the axon: Direct measurement of tubulin and actin as polymer
and monomer in axoplasm. The Journal of Cell Biology, 98,
2064–2076.
Munch, C., Rosenbohm, A., Sperfeld, A. D., Uttner, I., Reske, S.,
Krause, B. J., . . . Ludolph, A. C. (2005). Heterozygous R1101K
mutation of the DCTN1 gene in a family with ALS and FTD.
Annals of Neurology, 58, 777–780.
Munoz, L., Ralay Ranaivo, H., Roy, S. M., Hu, W., Craft, J. M.,
McNamara, L. K., . . . Watterson, D. M. (2007). A novel p38
alpha MAPK inhibitor suppresses brain proinflammatory cyto-
kine up-regulation and attenuates synaptic dysfunction and
behavioral deficits in an Alzheimer’s disease mouse model.
Journal of Neuroinflammation, 4, 21.
Nath, A. (2002). Human immunodeficiency virus (HIV) proteins in
neuropathogenesis of HIV dementia. The Journal of Infectious
Diseases, 186(Suppl 2): S193–S198.
Oh, S. K., Cruikshank, W. W., Raina, J., Blanchard, G. C., Adler,
W. H., Walker, J., . . . Kornfeld, H. (1992). Identification of
HIV-1 envelope glycoprotein in the serum of AIDS and ARC
patients. Journal of Acquired Immune Deficiency Syndromes, 5,
251–256.
Oh, S. B., Tran, P. B., Gillard, S. E., Hurley, R. W., Hammond, D.
L., Miller, R. J. (2001). Chemokines and glycoprotein120 pro-
duce pain hypersensitivity by directly exciting primary nocicep-
tive neurons. The Journal of Neuroscience, 21, 5027–5035.
Phillips, T. J., Cherry, C. L., Cox, S., Marshall, S. J., & Rice, A. S.
(2010). Pharmacological treatment of painful HIV-associated
sensory neuropathy: A systematic review and meta-analysis of
randomised controlled trials. PLoS One, 5, e14433.
Pigino, G., Morfini, G., Atagi, Y., Deshpande, A., Yu, C.,
Jungbauer, L., . . . Brady, S. (2009). Disruption of fast axonal
transport is a pathogenic mechanism for intraneuronal amyloid
beta. Proceedings of the National Academy of Sciences of the
United States of America, 106, 5907–5912.
Platholi, J., Federman, A., Detert, J. A., Heerdt, P., & Hemmings,
Jr. H. C. (2014). Regulation of protein phosphatase 1I by
Cdc25C-associated kinase 1 (C-TAK1) and PFTAIRE protein
kinase. Journal of Neurochemistry, 289, 23893–23900.
Politi, C., Del Turco, D., Sie, J. M., Golinski, P. A., Tegeder, I.,
Deller, T., . . . Schultz, C. (2008). Accumulation of phosphory-
lated I kappaB alpha and activated IKK in nodes of Ranvier.
Neuropathology and Applied Neurobiology, 34, 357–365.
Puls, I., Jonnakuty, C., LaMonte, B. H., Holzbaur, E. L., Tokito,
M., Mann, E., . . . Fischbeck, K. H. (2003). Mutant dynactin in
motor neuron disease. Nature Genetics, 33, 455–456.
Reid, E., Kloos, M., Ashley-Koch, A., Hughes, L., Bevan, S.,
Svenson, I. K., . . . Marchuk, D. A. (2002). A kinesin heavy
chain (KIF5A) mutation in hereditary spastic paraplegia
(SPG10). American Journal of Human Genetics, 71,
1189–1194.
Robinson, B., Li, Z., & Nath, A. (2007). Nucleoside reverse tran-
scriptase inhibitors and human immunodeficiency virus proteins
cause axonal injury in human dorsal root ganglia cultures.
Journal of Neurovirology, 13, 160–167.
Sagot, Y., Vejsada, R., & Kato, A. C. (1997). Clinical and molecu-
lar aspects of motoneurone diseases: Animal models, neuro-
trophic factors and Bcl-2 oncoprotein. Trends in
Pharmacological Sciences, 18, 330–337.
Sakurai, H. (2012). Targeting of TAK1 in inflammatory disorders
and cancer. Trends in Pharmacological Sciences, 33, 522–530.
Schneider, J., Kaaden, O., Copeland, T. D., Oroszlan, S., &
Hunsmann, G. (1986). Shedding and interspecies type sero-reac-
tivity of the envelope glycopolypeptide gp120 of the human
immunodeficiency virus. The Journal of General Virology,
67(Pt 11): 2533–2538.
Schultz, C., Konig, H. G., Del Turco, D., Politi, C., Eckert, G. P.,
Ghebremedhin, E., . . . Deller, T. (2006). Coincident enrichment
of phosphorylated IkappaBalpha, activated IKK, and phos-
phorylated p65 in the axon initial segment of neurons.
Molecular and Cellular Neurosciences, 33, 68–80.
Shastry, P., Basu, A., & Rajadhyaksha, M. S. (2001).
Neuroblastoma cell lines—A versatile in vitro model in neuro-
biology. The International Journal of Neuroscience, 108,
109–126.
Singh, I. N., El-Hage, N., Campbell, M. E., Lutz, S. E., Knapp, P.
E., Nath, A., . . . Hauser, K. F. (2005). Differential involvement
of p38 and JNK MAP kinases in HIV-1 Tat and gp120-induced
apoptosis and neurite degeneration in striatal neurons.
Neuroscience, 135, 781–790.
Singh, I. N., Goody, R. J., Dean, C., Ahmad, N. M., Lutz, S. E.,
Knapp, P. E., . . . Hauser, K. F. (2004). Apoptotic death of stri-
atal neurons induced by human immunodeficiency virus-1 Tat
and gp120: Differential involvement of caspase-3 and endo-
nuclease G. Journal of Neurovirology, 10, 141–151.
Berth et al. 17
Song, Y., & Brady, S. T. (2013). Analysis of microtubules in iso-
lated axoplasm from the squid giant axon. Methods in Cell
Biology, 115, 125–137.
Song, Y., Kang, M., Morfini, G., & Brady, S. T. (2016). Fast axonal
transport in isolated axoplasm from the squid giant axon.
Methods in Cell Biology, 131, 331–348.
Szebenyi, G., Morfini, G. A., Babcock, A., Gould, M., Selkoe, K.,
Stenoien, D. L., . . . Brady, S. T. (2003). Neuropathogenic forms
of huntingtin and androgen receptor inhibit fast axonal trans-
port. Neuron, 40, 41–52.
Takekawa, M., Tatebayashi, K., & Saito, H. (2005). Conserved
docking site is essential for activation of mammalian MAP
kinase kinases by specific MAP kinase kinase kinases.
Molecular Cell, 18, 295–306.
Toggas, S. M., Masliah, E., Rockenstein, E. M., Rall, G. F.,
Abraham, C. R., Mucke, L. (1994). Central nervous system
damage produced by expression of the HIV-1 coat protein
gp120 in transgenic mice. Nature, 367, 188–193.
Wilkerson, J. L., Gentry, K. R., Dengler, E. C., Wallace, J. A.,
Kerwin, A. A., Armijo, L. M., . . . Milligan, E. D. (2012).
Intrathecal cannabilactone CB(2)R agonist, AM1710, controls
pathological pain and restores basal cytokine levels. Pain, 153,
1091–1106.
Yi, Y., Lee, C., Liu, Q. H., Freedman, B. D., & Collman, R. G.
(2004). Chemokine receptor utilization and macrophage signal-
ing by human immunodeficiency virus type 1 gp120:
Implications for neuropathogenesis. Journal of Neurovirology,
10(Suppl 1): 91–96.
Zheng, J., Ghorpade, A., Niemann, D., Cotter, R. L., Thylin, M. R.,
Epstein, L., . . . Gendelman, H. E. (1999). Lymphotropic
virions affect chemokine receptor-mediated neural signaling
and apoptosis: Implications for human immunodeficiency
virus type 1-associated dementia. Journal of Virology, 73,
8256–8267.
Zheng, W., Ouyang, H., Zheng, X., Liu, S., Mata, M., Fink, D.
J., . . . Hao, S. (2011). Glial TNFalpha in the spinal cord regu-
lates neuropathic pain induced by HIV gp120 application in rats.
Molecular Pain, 7, 40.
18 ASN Neuro
